Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy
MedComm · 2023-12 · 4 (6)
DOI: 10.1002/mco2.422 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, 2023-12. Verfasst von Yan Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang China. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 200 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T cells have been successfully used in adoptive cell therapy for malignancies. However, some obstacles, including side effects such as graft‐versus‐host disease and cytokine release syndrome, therapy resistance, limited sources, as well as high cost, limited the application of CAR T cells. Recently, CAR natural killer (NK) cells have been pursued as the effector cells for adoptive immunotherapy for their attractive merits of strong intrinsic antitumor activity and relatively mild side effects. Additionally, CAR NK cells can be available from various sources and do not require strict human leukocyte antigen matching, which suggests them as promising “off‐the‐shelf” products for clinical application. Although the use of CAR NK cells is restrained by the limited proliferation and impaired efficiency within the immunosuppressive tumor microenvironment, further investigation in optimizing CAR structure and combination therapies will overcome these challenges. This review will summarize the advancement of CAR NK cells, CAR NK cell manufacture, the clinical outcomes of CAR NK therapy, the challenges in the field, and prospective solutions. Besides, we will discuss the emerging application of other immune cells for CAR engineering. Collectively, this comprehensive review will provide a valuable and informative summary of current progress and evaluate challenges and future opportunities of CAR NK cells in tumor treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang China.
- Key Laboratory of Hematologic Malignancies Diagnosis, and Treatment Hangzhou Zhejiang China.
- Department of Oncology Affiliated Hospital of Weifang Medical University School of Clinical Medicine Weifang Medical University Weifang Shandong China.
- Zhejiang University Cancer Center Hangzhou Zhejiang China.
- Zhejiang Provincial Clinical Research Center for Hematological Disorders Hangzhou Zhejiang China.
Zitieren
APA
Wang, Y., Jin, S., Zhuang, Q., Liu, N., Chen, R., Adam, S. A., Jin, J., & Sun, J. (2023). Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy. MedComm, 4(6). https://doi.org/10.1002/mco2.422
Vancouver
Wang Y, Jin S, Zhuang Q, Liu N, Chen R, Adam SA, et al. Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy. MedComm. 2023;4(6). doi:10.1002/mco2.422
BibTeX
@article{Wang2023,
author = {Wang, Yan and Jin, Shengjie and Zhuang, Qiqi and Liu, Na and Chen, Ruyi and Adam, Sofia Abdulkadir and Jin, Jie and Sun, Jie},
title = {Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy},
journal = {MedComm},
year = {2023},
volume = {4},
number = {6},
doi = {10.1002/mco2.422}
}
EUVIMED